相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1896
已完成
1
25.0%
尚未招募
1
25.0%
终止
2
50.0%
暂无批准数据
- African populations represent only 0.15% of GWAS participants and less than 2% of global genomic datasets, creating a critical data gap that limits disease research and precision medicine worldwide. - Several African nations including Tunisia, Egypt, Senegal, South Africa, Tanzania, and Kenya have launched or announced national genome projects, building on infrastructure developed during the COVID-19 pandemic. - Expanding pathogen genomic sequencing platforms to human genomics offers a sustainable pathway to address both noncommunicable diseases and pandemic preparedness across the continent. - Experts call for innovative funding mechanisms, regional collaboration hubs, and ethical governance frameworks to ensure African genomic data sovereignty and equitable participation in global precision medicine.
- A new €15.3 million EU-funded project, ACT-CHIK, will conduct a Phase Ib/III trial of the MV-CHIK chikungunya vaccine across Rwanda, Kenya, Nigeria, and Senegal, enrolling 940 participants including adults, adolescents, and children. - The MV-CHIK vaccine uses a measles virus Schwarz strain vector and has demonstrated satisfactory safety and immunogenicity in six prior Phase I/II trials involving approximately 600 adults. - The four-year initiative will prepare technology transfer of vaccine manufacturing to Institut Pasteur de Dakar, Africa's only WHO-prequalified vaccine manufacturer, supporting the African Union's goal of producing 60% of vaccines locally by 2040. - The international consortium spans seven partners across four continents, coordinated by Institut Pasteur, with the International Vaccine Institute serving as clinical trial sponsor.
- Researchers from King's College London and University of Oxford have published the first global standard for measuring outcomes in dengue treatment trials in The Lancet Infectious Diseases. - The new standard addresses longstanding discrepancies in trial measurements that have limited comparison and synthesis of evidence across dengue research studies. - With half the world's population at risk and dengue cases doubling in Europe to 304 locally acquired cases in 2024, the standardized approach could accelerate the path to finding treatments for this mosquito-borne viral disease. - The global consensus involved contributors from 36 countries and included people with lived experience of dengue fever to ensure the outcome scale reflects patient needs alongside clinical requirements.
